Jawaad Khokhar, MD
Endocrinology, Diabetes & Metabolism · Glen Burnie, MDNPI 1336272707
Payments from drug & device makers
Across 956 payments — averaging $161.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$113K
- Xeris Pharmaceuticals, Inc.$21K
- Sanofi-aventis U.S. LLC$13K
- Novo Nordisk$2K
- AstraZeneca$2K
- Lilly USA, LLC$875
- plus $4K from 28 others
What the payments were for
- Consulting fees$21,90014%
- Speaking & faculty fees$106,75069%
- Travel & lodging$10,2107%
- Food & beverage$15,81610%
- Education$660%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 211 | $113,035 |
| Xeris Pharmaceuticals, Inc. | 76 | $20,948 |
| Sanofi-aventis U.S. LLC | 43 | $12,647 |
| Novo Nordisk | 211 | $1,913 |
| AstraZeneca(2 entities) | 49 | $1,687 |
| Lilly USA, LLC | 75 | $875 |
| Mannkind Corporation | 82 | $716 |
| Boehringer Ingelheim | 36 | $475 |
| Dexcom, Inc. | 40 | $416 |
| Abbott | 28 | $313 |
| Johnson & Johnson | 26 | $214 |
| Amgen(2 entities) | 12 | $197 |
| Merck | 9 | $153 |
| Medtronic(2 entities) | 3 | $111 |
| AbbVie | 5 | $105 |
| Radius Health, Inc. | 4 | $98 |
| Shire North American Group Inc | 5 | $92 |
| Regeneron Healthcare Solutions, Inc. | 4 | $79 |
| Novartis | 3 | $77 |
| BETA Bionics, Inc. | 3 | $76 |
| Eisai Inc. | 4 | $75 |
| Tandem Diabetes Care, Inc. | 3 | $71 |
| Kyowa Kirin, Inc. | 3 | $62 |
| Amneal Pharmaceuticals LLC | 4 | $55 |
| Cequr Corporation | 2 | $54 |
| IBSA Pharma Inc. | 3 | $45 |
| Insulet Corporation | 2 | $42 |
| Amarin Pharma, Inc. | 2 | $41 |
| Bayer | 2 | $31 |
| Amphastar Pharmaceuticals, Inc. | 2 | $28 |
| Lifescan, Inc. | 1 | $20 |
| Clarus Therapeutics Inc. | 1 | $18 |
| Companion Medical, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$109,485
- RECORLEV$18,782
- TZIELD$11,956
- GVOKE HYPOPEN$1,300
- FARXIGA$572
How this compares
$154,802 in reported general payments places this provider in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
See all endocrinology, diabetes & metabolism providers in Maryland →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RecorlevLevoketoconazole | 19 | $808,691 |
| OzempicSemaglutide | 267 | $318,658 |
| MounjaroTirzepatide | 198 | $247,917 |
| JardianceEmpagliflozin | 109 | $147,258 |
| TrulicityDulaglutide | 100 | $138,714 |
| RybelsusSemaglutide | 87 | $119,157 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 98 | $103,439 |
| FarxigaDapagliflozin Propanediol | 96 | $86,604 |
| Xigduo XrDapaglifloz Propaned/Metformin | 83 | $81,020 |
| Tresiba Flextouch U-200Insulin Degludec | 44 | $76,615 |
| Tresiba Flextouch U-100Insulin Degludec | 59 | $33,169 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $22,767 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 12 | $21,772 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 29 | $14,469 |
| Novolog FlexpenInsulin Aspart | 45 | $12,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Xeris Pharmaceuticals, Inc.Recorlev | $20,948 | $808,69119 claims |
| Novo NordiskOzempic, Rybelsus | $1,913 | $437,816354 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $875 | $391,834317 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $475 | $250,697207 claims |
| AstraZenecaFarxiga | $1,687 | $86,60496 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $55 | $2,367193 claims |
| AbbVieSynthroid | $105 | $1,50833 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.
Other endocrinology, diabetes & metabolism in Glen Burnie
- Jean ParkBaltimore$3.7M
- Michael DempseyRockville$2.7M
- Ilias SpanakisBaltimore$2.6M
- Helena RodbardRockville$2.4M
- Daniel GozziSuitland$1.2M
- Martin SarkarFrederick$1.1M
- Romeu AzevedoCamp Springs$1.1M
- Nicholas ArgentoLaurel$1.1M
- Philip LevinBaltimore$702K
- David BrownRockville$497K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.